Correspondence on 'Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'.

Ann Rheum Dis

Department of Dermatology, Henry Ford Health System, Detroit, Michigan, USA

Published: October 2021

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440471	PMC
http://dx.doi.org/10.1136/annrheumdis-2021-220736	DOI Listing

Publication Analysis

correspondence 'immunogenicity

'immunogenicity safety

safety anti-sars-cov-2

anti-sars-cov-2 mrna

mrna vaccines

vaccines patients

patients chronic

chronic inflammatory

inflammatory conditions

conditions immunosuppressive

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!